Vertex Pharmaceuticals has released the first data from the initial cohorts of an open-label Phase IIa study of VX-135, Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, in combination with daclatasvir, Bristol-Myers Squibb‘s NS5A replication complex inhibitor. In an intent-to-treat analysis, the sustained viral response rate four weeks after the completion of treatment (SVR4) was 83% (10 of 12) in treatment-naïve genotype 1 patients who received 200 mg of VX-135 i...